3T Intraoperative MRI for Management of Pediatric CNS Neoplasms

A.F. Choudhri, P. Klimo, Jr, T.S. Auschwitz, M.T. Whitehead and F.A. Boop

AJNR Am J Neuroradiol 2014, 35 (12) 2382-2387
doi: https://doi.org/10.3174/ajnr.A4040
http://www.ajnr.org/content/35/12/2382

This information is current as of August 15, 2024.
ABSTRACT

BACKGROUND AND PURPOSE: High-field-strength intraoperative MR imaging has emerged as a powerful adjunct for resection of brain tumors. However, its exact role has not been firmly established. We sought to determine the impact of 3T-intraoperative MRI on the surgical management of childhood CNS tumors.

MATERIALS AND METHODS: We evaluated patient data from a single academic children’s hospital during a consecutive 24-month period after installation of a 3T-intraoperative MRI. Tumor location, histology, surgical approach, operating room time, presence and volume of residual tumor, need for tumor and non-tumor-related reoperation, and anesthesia- and MR imaging–related complications were evaluated. Comparison with pre-intraoperative MRI controls was performed.

RESULTS: One hundred ninety-four patients underwent intraoperative MRI–guided surgery. Of these, 168 were 18 years or younger (mean, 8.9 ± 5.0 years; 108 males/60 females). There were 65 posterior fossa tumors. The most common tumors were pilocytic astrocytoma (n = 31, 19%), low-grade glioma (n = 31, 19%), and medulloblastoma (n = 20, 12%). An average of 1.2 scanning sessions was performed per patient (maximum, 3). There were no MR imaging–related safety issues. Additional tumor was resected after scanning in 21% of patients. Among patients with a preoperative goal of gross total resection, 93% achieved this goal. The 30-day reoperation rate was <1% (n = 1), and no patient required additional postoperative MR imaging during the same hospital stay.

CONCLUSIONS: Intraoperative MRI is safe and increases the likelihood of gross total resection, albeit with increased operating room time, and reduces the need for early reoperation or repeat sedation for postoperative scans in children with brain tumors.

ABBREVIATIONS: FSPGR = fast-spoiled gradient recalled; iMRI = intraoperative MRI
years or younger who underwent iMRI-guided resection. Preoperative, intraoperative, MR imaging–related, and postoperative parameters and outcomes were recorded.

Preoperative parameters evaluated included the age, sex, number of prior tumor resections or biopsies, and the presence of a preoperative shunt. Intraoperative parameters evaluated included operating room entry time, time of initial skin incision and skin closure, operating room exit time, patient position, surgical approach, estimated blood loss, and anesthesia-related complications. We determined whether frameless stereotactic navigation was used and whether this was performed by using scans obtained in the operating room or before arrival in the operating room.

MR imaging parameters evaluated included the number of intraoperative scans, the time required to place the MR imaging coils and bring the scanner into the room, the number of scout-localizers required, the total amount of intravenous contrast administered, and any MR imaging–related complications. The presence of residual tumor on MR imaging scans was also documented. The extent of resection was graded as gross total resection if >98% of the tumor was resected, near-total if >90% was resected, and subtotal if <90% was resected.

Postoperative parameters included tumor histology, length of stay (intensive care, total hospital admission), disposition at time of discharge (home versus other facility), 7- and 30-day reoperation rates, mortality, and surgical site complications.

**MR Imaging Scanner and Imaging Protocol**

iMRI scans were performed with a 3T unit (Magnetom Verio 3T; Siemens, Erlangen, Germany), which was brought into the operating room via a ceiling-mounted track system (IMRIS-neuro; IMRIS, Winnipeg, Manitoba, Canada). A 2-part split-array 8-channel head coil (HC-300; IMRIS-neuro) was used, with one 4-channel component of the coil placed inferior to the patient’s head and one 4-channel component placed superior to the patient’s head.

For the first 12 months, the routine intraoperative scanning protocol included axial and coronal T1-weighted images before and after contrast administration and an axial T2-weighted sequence and diffusion-weighted imaging. Additional planes were used in select cases as needed, most often sagittal T1 postcontrast for posterior fossa tumors. After 12 months, the protocol was revised to include axial 3D fast-spoiled gradient recalled (FSPGR) images before and after contrast administration, an axial T2-weighted image, and axial diffusion-weighted images. The axial T2-weighted image was obtained immediately after contrast administration to allow a contrast agent infusion delay before the FSPGR images. Subtraction imaging was performed between the pre- and postcontrast FSPGR sequence, and FSPGR reformats were performed in the sagittal and coronal planes.

Imaging studies were interpreted at the time of scanning by 1 of 2 fellowship-trained board-certified neuroradiologists (A.F.C. or M.T.W.) and were reviewed in direct consultation with the attending neurosurgeon (F.A.B. or P.K.).

**Historical Comparison**

A hospital neuro-oncology data base was queried to evaluate the incidence of tumor-related reoperations at our hospital in the time before institution of the iMRI program.

<table>
<thead>
<tr>
<th>Table 1: Tumor location</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>Supratentorial (NOS)</td>
</tr>
<tr>
<td>Infratentorial (not brain stem)</td>
</tr>
<tr>
<td>Brain stem</td>
</tr>
<tr>
<td>Midbrain/pineal</td>
</tr>
<tr>
<td>Third ventricular/suprasellar</td>
</tr>
<tr>
<td>Deep gray nuclei</td>
</tr>
<tr>
<td>Cervical spine/skull base</td>
</tr>
</tbody>
</table>

Note:—NOS indicates not otherwise specified.

<table>
<thead>
<tr>
<th>Table 2: Tumor histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histology</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>Pilocytic astrocytoma</td>
</tr>
<tr>
<td>Low-grade glioma</td>
</tr>
<tr>
<td>Medulloblastoma/PNET</td>
</tr>
<tr>
<td>Ependymoma</td>
</tr>
<tr>
<td>High-grade glioma</td>
</tr>
<tr>
<td>Gangliogioma</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

Note:—PNET indicates primitive neuroectodermal tumor.

**Data Collection and Statistics**

Data were stored on a spreadsheet (Excel 2011; Microsoft, Redmond, Washington). Data were analyzed by using Excel and SPSS, Version 20 (IBM, Armonk, New York). Discrete variables were compared by using the Fisher exact test. Continuous variables were compared by using the Kruskall-Wallis test, with a nonparametric posttest, or a Student t test when data followed a Gaussian distribution. A P value <.05 was considered significant.

**RESULTS**

**Patient Demographics**

One hundred ninety-four patients underwent iMRI-guided surgery at our institution in the 24 months after installation. Of these, 168 (87%) were 18 years or younger (mean, 8.9 ± 5.0; range, 1.2–18.5 years; median, 8.0 years). There were 60 females and 108 males. Sixty-five (39%) tumors were located in the posterior fossa (Table 1). The most common tumors were pilocytic astrocytoma (n = 31, 19%), low-grade glioma (n = 31, 19%), and medulloblastoma (n = 20, 12%) (Table 2). Prior tumor resection was performed in 60 patients (38%), and 34 (21%) had pre-existing CSF shunts. The prone position was used in 79 patients; supine, in 70; and lateral decubitus, in 19.

**MR Imaging Scans**

Within the pediatric subset of patients, an average of 1.2 intraoperative scanning sessions per patient was performed (median, 1; maximum, 3 scan sessions). There were no MR imaging–related safety issues. Intraoperative gadolinium was administered in 152 patients (90%). For patients receiving gadolinium for the intraoperative scan, an average of 1.1 doses was administered (median, 1; range, 1–3). The dose for the first 2 administrations was 0.1 mmol/kg of gadopentetate dimeglumine. When required, the third administration was a half-dose (0.05-mmol/kg gadopentetate dimeglumine).

**Operating Room Workflow**

The mean time in the operating room, from the patient entering the room to exiting the room, was 428 ± 143 minutes (range, 2382–87 Dec 2014 www.ajnr.org 2383
158–958 minutes; median, 415 minutes) (Table 3). The time from operating room entry to initial skin incision was 91 ± 40 minutes (range, 19–237 minutes; median, 78 minutes).

Thirty-four patients underwent a stereotactic MR imaging scan in the operating room before starting the case, with a time from entering the operating room to initial skin incision of 145 ± 36 minutes (median, 145 minutes). Compared with the 134 patients who did not have a stereotactic MR imaging scan in the operating room before starting the procedure, which included 98 patients with previously performed stereotactic scans and 36 performed without stereotactic guidance, the mean time from entering the room to initial skin incision was 69 ± 20 minutes (median, 63 minutes; P < .0001).

### Peri- and Postoperative Outcomes

The preoperative surgical goal was individualized, primarily depending on the tumor location: gross total resection (n = 112), debulking (n = 40), biopsy (n = 12), and other (n = 4).

Additional tumor was resected in 35 (21%) patients (Fig 1) after scanning. Intraoperatively acquired volumetric images were merged with the stereotactic navigation study in 22 patients to correct for brain shift and guide continuation of resection. Of 112 with a goal of gross total resection, 26 (23%) had further resection of the lesion, and at the end of the procedure, 104 of these patients (93%) had gross total resection, with 6 having near-total resection and 2 having subtotal resection. Of 40 patients with a preoperative goal of debulking, 2 had gross total resection, 20 had near-total resection, 16 had subtotal resection, and 2 had biopsy.

Estimated

<table>
<thead>
<tr>
<th>Table 3: Mean time in the operating room*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total OR Time</strong></td>
</tr>
<tr>
<td>-------------------</td>
</tr>
<tr>
<td><strong>All patients</strong></td>
</tr>
<tr>
<td><strong>Group 1</strong></td>
</tr>
<tr>
<td><strong>Group 2 (all pts)</strong></td>
</tr>
<tr>
<td><strong>Group 2a</strong></td>
</tr>
<tr>
<td><strong>Group 2b</strong></td>
</tr>
<tr>
<td><strong>P (g1 vs g2)</strong></td>
</tr>
<tr>
<td><strong>P (g2a vs g2b)</strong></td>
</tr>
</tbody>
</table>

* Time is listed in minutes; numbers in parentheses are the median values. Group 1 indicates those with an intraoperative stereotactic scan; group 2, no intraoperative stereotactic scan; group 2a, no stereotactic navigation used; group 2b, stereotactic scan obtained prior to arrival in the operating room.

**Note:** OR indicates operating room; pts, patients; g1, group 1; g2, group 2; g2a, group 2a; g2b, group 2b; NS, not significant.

**FIG 1.** A, Axial T2-weighted image shows a mass in the fourth ventricle in a 9-year-old boy. B, Axial T1-weighted image after gadolinium administration shows heterogeneous enhancement within the lesion. C, Axial T1 postgadolinium image from intraoperative MRI shows residual tumor along the right superolateral aspect of the resection cavity. D, Axial T1 postgadolinium image from intraoperative MRI after continuation of resection shows removal of the previously seen residual lesion. A rim of enhancement was seen along the margins of the resection cavity; however, no discrete lesion was identified on surgical inspection of the margins. E, Axial T2WI shows a margin of T2 shortening with subjacent edema in the areas of enhancement, a pattern that corresponds to recent use of bipolar electrocautery. On this basis, no further resection was performed.
blood loss was 141 ± 137 mL (range, 10–1000 mL; median, 100 mL).

One hundred fifty-one patients went to the intensive care unit after surgery, and 17 did not. The average intensive care unit length of stay was 2.3 ± 3.9 days (range, 0–35 days; median, 1 day). The total hospital length of stay for all patients was 7.6 ± 5.3 days (range, 1–35 days; median, 6 days). Discharge disposition was most commonly to home (n = 99). Twenty-nine patients were transferred to a partner institution (n = 29) for continued convalescence and others to a hospital-partnered family temporary housing (n = 23).

The tumor-related reoperation rate was 0% at 7 days and 1% at 30 days (1 of 168). The one patient who required reoperation was an 11-year-old boy who had a right frontal lesion originally postulated to be a low-grade lesion. After pathologic determination of a high-grade glioma, the decision was made to further extend the margins to ensure the removal of nonenhancing T2/FLAIR signal abnormality that was originally thought to represent edema. The all-cause reoperation rate was 6% at 7 days (n = 10) and 7% at 30 days (n = 11), with reoperations for shunt placement/revision (n = 6), pseudomeningocele (n = 3), and intracranial pressure monitor placement (n = 1) within the first 7 days and for additional tumor resection (n = 1) within the first 30 days.

The 30-day mortality rate after iMRI-guided tumor resection was 0%. At 30 days, 2 patients developed superficial wound infections and a third patient developed a deep infection. There have been no clinical signs of contrast-induced nephrogenic systemic fibrosis in any of the patients.

In the 12 months before instituting the iMRI program, 104 patients underwent tumor resection at our institution (63 males, 41 females). The 30-day tumor-related reoperation rate was 8% (8 of 104 patients) (P = .002 versus the iMRI cohort).

**DISCUSSION**

We have demonstrated that high-field-strength iMRI in children is safe; negates the need for sedation and postoperative MR imaging requiring travel from the safe confines of the intensive care unit; and markedly reduces the need for early reoperation by maximizing tumor resectability. The price of this technology is added operating room time, with an intraoperative scan adding approximately 45–60 minutes to a case, including the time for safety checks, patient preparation, moving the MR imaging scanner, and performing the scan. Performing stereotactic navigation sequences in the operating room before skin incision further prolongs operating room time. The preoperative preparation time, from entering the room to initial skin incision, was approximately 55 minutes longer when an intraoperative stereotactic scan was performed compared with use of a pre-existing scan. However, we have had no anesthesi or MR imaging–related complications, and our wound infection rates are no greater than those in historical controls. Continued follow-up is needed to assess the incidence of tumor recurrence, postoperative neurologic and cognitive deficits, and ultimately survival.

There are unique challenges in evaluating and interpreting intraoperative MR images. Gross changes in lesional signal inten-
sity, diffusion characteristics, and enhancement patterns between the preoperative MR imaging and iMRI are often postoperative in nature rather than a reflection of residual tumor. For example, there are often thin areas of enhancement marginating the operative cavity (Fig 2), even in locations where there was no enhancing tumor on preoperative imaging. In most cases, these areas of enhancement most likely represent hyperemia/engorged vasculature and regional small-vessel permeability, especially if electrocautery (ie, bipolar) was performed. Intrinsic T1 shortening from blood products can be mistaken for enhancement if comparison with precontrast T1 imaging is not performed (Fig 2D), and subtraction imaging can help confirm this. Granulation tissue does not develop in the immediate intraoperative setting. Distinction of vascular enhancement from trace residual tumor may be difficult or impossible, particularly if the tumor shows marked preprocedural enhancement or if the enhancement is nodular in character. In equivocal cases, these areas should be explored intraoperatively or subject to higher scrutiny on follow-up examinations.

Multiple iterations of intraoperative scanning in patients with enhancing lesions requires repeat administration of intravenous gadolinium. Accordingly, care must be taken to ensure that there are no secondary signs of acute renal dysfunction, such as decreased urine output, to reduce the risk of nephrogenic systemic fibrosis. Use of half-dose (0.05 mmol/kg) contrast, possibly with high relaxivity and/or macrocyclic gadolinium chelates, may help mitigate this risk.

Little is known about the normal appearance of an active operative cavity after multiple contrast agent doses. The imaging appearance is complicated by the presence of an admixture of contrast material injected at 2 different time points. Theoretically, both false-positive and false-negative findings of residual tumor could be possible in patients who have received >1 contrast agent dose during a short time. Nonetheless, there have been no known instances of false-positive or false-negative tumor residual in our experience thus far.

For various reasons, image distortion may be present in patients undergoing iMRI. First, suboptimal patient positioning with respect to the magnet isocenter can result in spatial-resolution distortions. Paramagnetic susceptibility artifacts from blood products and gas can cause image distortion. These entities have major implications for iMRI. Even subtle differences between apparent and actual lesion location because of image distortion could alter the expected surgical outcome.

Performing an intraoperative MR imaging decreases the need for postoperative imaging and, in the case of CT, radiation exposure. Some patients without visible complications on the iMRI scan may be able to be followed in a step-down bed as opposed to a full intensive care unit bed. No repeat MR imaging scans were performed during the first week after resection in patients who had an iMRI after tumor resection.

Alternative intraoperative imaging modalities have been described, in particular sonography, however predominantly related to adult gliomas. Few uses of sonography have been shown in pediatric tumors. Sonography is highly operator-dependent, and proper orientation with respect to the resection cavity can be difficult. iMRI allows spatial localization of the resection cavity and possible residual tumor, in a manner that easily compares with preoperative imaging and can serve as a comparison study for postoperative follow-up scans.

In addition to brain tumor resection, iMRI may have other roles in the pediatric population. It can be used to confirm shunt placement, perhaps in a patient with multiloculated hydrocephalus; to confirm biopsy location in a suspected demyelinating disorder or vasculitis; in surgery for vascular lesions; and for confirmation of resection margins in epilepsy surgery.

Success of high-field-strength iMRI requires careful attention to safety, and accordingly, patients with some implanted medical devices may not be able to safely undergo iMRI-guided surgery. Several patients at our institution were unable to undergo iMRI-guided surgery because they had implanted devices that were not cleared for 3T scanning.

The large-bore scanner (70 cm) allowed patients to be scanned in various positions; however, upright surgery is not possible with this system. Additionally, the patient cannot fully enter the bore of the magnet, and tumors of the lower cervical spine and thoracic spine could not be imaged with current technology.

Successful implementation of an iMRI program requires collaboration, and accordingly, all cases at our institution are reviewed by the neuroradiologist and neurosurgeon before the operation to identify the goals of the operation and the intended approach. All iMRI scans are interpreted with the neuroradiologist in the operative suite at the time of scanning, providing real-time consultation with the neurosurgeon.

Future work will include outcome analysis looking at long-term disease-free survival and mortality. Additionally, a detailed cost-analysis will be helpful to account for the expenditures on the device itself and the increased operating room time.

**CONCLUSIONS**

In this series, the early tumor reoperation rate reduced from 8% to <1% after instituting an iMRI program, which may result in reduced tumor recurrence and improved survival. If successful, an iMRI program can create a new paradigm for tumor treatment and establish the role for integrated real-time neuroradiology-neurosurgery collaboration for the resection of pediatric CNS tumors, which will translate into achieving optimal patient outcomes.

**REFERENCES**